| | | | |
AUC
|
|---|
|
cohort
|
regimen
|
patients
|
responders
|
CEI1
|
CEI2
|
CEI3
|
CEI4
|
CEI5
|
CEI6
|
|
EORTC
|
FEC
|
37
|
16
|
0.73R*
|
0.57
|
0.51R
|
0.61
|
0.56
|
0.54
|
|
MDA1
|
TFAC
|
27
|
13
|
0.78 **
|
0.62
|
0.77**
|
0.61R
|
0.53
|
0.61
|
|
MDA/MAQC
|
TFAC
|
30
|
9
|
0.77*
|
0.66
|
0.78*
|
0.62R
|
0.58
|
0.54
|
|
DFCI2
|
P
|
24
|
4
|
0.73
|
0.72R
|
0.50
|
0.52R
|
0.52R
|
0.57R
|
|
JBI2
|
E
|
43
|
4
|
0.85R*
|
0.73R
|
0.53
|
0.88**
|
0.58R
|
0.72
|
- Each CEI was evaluated as a univariate predictor of pathological complete response or residual disease using the area under the ROC curve (AUC). Chemotherapy regimens are indicated: A, doxorubicin; C, cyclophosphamide; E, epirubicin; F, 5-fluorouracil; P, either cisplatin or carboplatin; T, either paclitaxel or docetaxel. The CEIs were derived from four independent DNBC cohorts not shown in this table. * P < 0.05; ** P < 0.01. R: AUC is estimated based on association to residual disease (RD).
